老年患者降低LDL胆固醇的疗效与安全性:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE与Embase(2015年3月1日至2020年8月14日),纳入2018年美国心脏病学会与美国心脏协会指南推荐的他汀、依折麦布、PCSK9抑制剂心血管结局随机对照试验,要求中位随访至少2年并有≥75岁患者数据,排除仅纳入心力衰竭或透析患者的试验。29项试验共244 090例患者,其中21 492例(8.8%)≥75岁;中位随访2.2至6.0年。老年患者LDL胆固醇每降低1 mmol/L,主要血管事件(n=3519)风险降低26%(RR 0.74 [95% CI 0.61-0.89];p=0.0019),与<75岁患者的风险降低无统计学显著差异(0.85 [0.78-0.92];pinteraction=0.37)。老年患者中他汀(0.82 [0.73-0.91])与非他汀治疗(0.67 [0.47-0.95];pinteraction=0.64)的RR无统计学差异,复合终点各组分均见获益。
要点
- ≥75岁患者LDL胆固醇每降低1 mmol/L,主要血管事件风险降低26%(RR 0.74 [95% CI 0.61-0.89];p=0.0019)。
- 老年患者与<75岁患者的风险降低无统计学显著差异(0.85 [0.78-0.92];pinteraction=0.37)。
- 老年患者中他汀(RR 0.82 [0.73-0.91])与非他汀治疗(RR 0.67 [0.47-0.95];pinteraction=0.64)的RR无统计学差异。
- 老年患者中各复合终点组分均获益:心血管死亡0.85 [0.74-0.98]、心肌梗死0.80 [0.71-0.90]、卒中0.73 [0.61-0.87]、冠状动脉血运重建0.80 [0.66-0.96]。
适用人群与场景
- ≥75岁患者,数据来自29项随机对照试验中的21 492例(8.8%);其中他汀试验11 750例(54.7%)、依折麦布试验6209例(28.9%)、PCSK9抑制剂试验3533例(16.4%)。
- 纳入标准:2018年美国心脏病学会与美国心脏协会指南推荐的LDL胆固醇降低药物的心血管结局随机对照试验,中位随访至少2年,且有≥75岁患者数据。
- 排除仅纳入心力衰竭或透析患者的试验,因指南不推荐这类无其他适应证的患者接受降脂治疗。
研究设计与关键结果
- 系统评价与Meta分析,纳入6篇文章,包括胆固醇治疗试验协作组Meta分析中的24项试验加5项独立试验,共29项试验、244 090例患者,其中21 492例(8.8%)≥75岁;中位随访2.2至6.0年。
- 主要终点:老年患者LDL胆固醇每降低1 mmol/L,主要血管事件(心血管死亡、心肌梗死或其他急性冠脉综合征、卒中或冠状动脉血运重建的复合终点)风险降低26%(n=3519;RR 0.74 [95% CI 0.61-0.89];p=0.0019),与<75岁患者(0.85 [0.78-0.92];pinteraction=0.37)无统计学显著差异。
- 老年患者中他汀(RR 0.82 [95% CI 0.73-0.91])与非他汀治疗(RR 0.67 [95% CI 0.47-0.95];pinteraction=0.64)的RR无统计学差异。
- 老年患者各复合终点组分:心血管死亡0.85 [95% CI 0.74-0.98]、心肌梗死0.80 [0.71-0.90]、卒中0.73 [0.61-0.87]、冠状动脉血运重建0.80 [0.66-0.96]。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析;资助:无。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在≥75岁患者中,降脂降低心血管事件的效果与<75岁患者相同;这些结果应强化指南对老年患者使用降脂治疗(包括非他汀治疗)的推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients.
METHODS: In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without any language restrictions. We included randomised controlled trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 American College of Cardiology and American Heart Association guidelines, with a median follow-up of at least 2 years and data on older patients (aged ≥75 years). We excluded trials that exclusively enrolled participants with heart failure or on dialysis because guidelines do not recommend lipid-lowering therapy in such patients who do not have another indication. We extracted data for older patients using a standardised data form for aggregated study-level data. We meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L reduction in LDL cholesterol.
FINDINGS: Data from six articles were included in the systematic review and meta-analysis, which included 24 trials from the Cholesterol Treatment Trialists' Collaboration meta-analysis plus five individual trials. Among 244 090 patients from 29 trials, 21 492 (8·8%) were aged at least 75 years, of whom 11 750 (54·7%) were from statin trials, 6209 (28·9%) from ezetimibe trials, and 3533 (16·4%) from PCSK9 inhibitor trials. Median follow-up ranged from 2·2 years to 6·0 years. LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61-0·89]; p=0·0019), with no statistically significant difference with the risk reduction in patients younger than 75 years (0·85 [0·78-0·92]; pinteraction=0·37). Among older patients, RRs were not statistically different for statin (0·82 [0·73-0·91]) and non-statin treatment (0·67 [0·47-0·95]; pinteraction=0·64). The benefit of LDL cholesterol lowering in older patients was observed for each component of the composite, including cardiovascular death (0·85 [0·74-0·98]), myocardial infarction (0·80 [0·71-0·90]), stroke (0·73 [0·61-0·87]), and coronary revascularisation (0·80 [0·66-0·96]).
INTERPRETATION: In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. These results should strengthen guideline recommendations for the use of lipid-lowering therapies, including non-statin treatment, in older patients.
参考来源
- Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020. PMID: 33186535. doi:10.1016/S0140-6736(20)32332-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。